{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T13:12:39Z","timestamp":1792069959952,"version":"4.4.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s12325-024-03073-8","type":"journal-article","created":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T17:51:49Z","timestamp":1735581109000},"page":"1147-1164","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Safety of Fezolinetant for Treatment of Moderate to Severe Vasomotor Symptoms Due to Menopause: Pooled Analysis of Three Randomized Phase 3 Studies"],"prefix":"10.1007","volume":"42","clinical-trial-number":[{"clinical-trial-number":"nct04003155","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04003142","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04003389","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6826-0787","authenticated-orcid":false,"given":"Risa","family":"Kagan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8046-0303","authenticated-orcid":false,"given":"Antonio","family":"Cano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1713-6396","authenticated-orcid":false,"given":"Rossella E.","family":"Nappi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marci L.","family":"English","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shayna","family":"Mancuso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6295-5166","authenticated-orcid":false,"given":"Faith D.","family":"Ottery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,30]]},"reference":[{"issue":"4","key":"3073_CR1","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/nrendo.2017.180","volume":"14","author":"P Monteleone","year":"2018","unstructured":"Monteleone P, Mascagni G, Giannini A, Genazzani AR, Simoncini T. Symptoms of menopause - global prevalence, physiology and implications. Nat Rev Endocrinol. 2018;14(4):199\u2013215.","journal-title":"Nat Rev Endocrinol"},{"issue":"9","key":"3073_CR2","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1097\/GME.0000000000000196","volume":"21","author":"EW Freeman","year":"2014","unstructured":"Freeman EW, Sammel MD, Sanders RJ. Risk of long-term hot flashes after natural menopause: evidence from the Penn Ovarian Aging Study cohort. Menopause. 2014;21(9):924\u201332.","journal-title":"Menopause"},{"issue":"3","key":"3073_CR3","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1590\/1516-4446-2020-0871","volume":"43","author":"MB Jaeger","year":"2021","unstructured":"Jaeger MB, Min\u00e1 CS, Alves S, Schuh GJ, Wender MC, Manfro GG. Negative affect symptoms, anxiety sensitivity, and vasomotor symptoms during perimenopause. Braz J Psychiatry. 2021;43(3):277\u201384.","journal-title":"Braz J Psychiatry"},{"issue":"2","key":"3073_CR4","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1080\/13697137.2018.1430131","volume":"21","author":"RC Thurston","year":"2018","unstructured":"Thurston RC. Vasomotor symptoms: natural history, physiology, and links with cardiovascular health. Climacteric. 2018;21(2):96\u2013100.","journal-title":"Climacteric"},{"issue":"3","key":"3073_CR5","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1097\/GRF.0000000000000639","volume":"64","author":"AJ Voedisch","year":"2021","unstructured":"Voedisch AJ, Dunsmoor-Su R, Kasirsky J. Menopause: a global perspective and clinical guide for practice. Clin Obstet Gynecol. 2021;64(3):528\u201354.","journal-title":"Clin Obstet Gynecol"},{"issue":"3","key":"3073_CR6","first-page":"203","volume":"13","author":"MT Makara-Studzi\u0144\u015bka","year":"2014","unstructured":"Makara-Studzi\u0144\u015bka MT, Kry\u015b-Noszczyk KM, Jakiel G. Epidemiology of the symptoms of menopause\u2014an intercontinental review. Prz Menopauzalny. 2014;13(3):203\u201311.","journal-title":"Prz Menopauzalny"},{"issue":"3","key":"3073_CR7","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.ecl.2015.05.001","volume":"44","author":"N Santoro","year":"2015","unstructured":"Santoro N, Epperson CN, Mathews SB. Menopausal symptoms and their management. Endocrinol Metab Clin North Am. 2015;44(3):497\u2013515.","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"4","key":"3073_CR8","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1001\/jamainternmed.2014.8063","volume":"175","author":"NE Avis","year":"2015","unstructured":"Avis NE, Crawford SL, Greendale G, et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med. 2015;175(4):531\u20139.","journal-title":"JAMA Intern Med"},{"issue":"5","key":"3073_CR9","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1097\/GME.0000000000001949","volume":"29","author":"Q Yu","year":"2022","unstructured":"Yu Q, Chae HD, Hsiao SM, et al. Prevalence, severity, and associated factors in women in East Asia with moderate-to-severe vasomotor symptoms associated with menopause. Menopause. 2022;29(5):553\u201363.","journal-title":"Menopause"},{"issue":"8","key":"3073_CR10","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1097\/GME.0000000000001793","volume":"28","author":"RE Nappi","year":"2021","unstructured":"Nappi RE, Kroll R, Siddiqui E, et al. Global cross-sectional survey of women with vasomotor symptoms associated with menopause: prevalence and quality of life burden. Menopause. 2021;28(8):875\u201382.","journal-title":"Menopause"},{"issue":"2","key":"3073_CR11","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.maturitas.2008.12.006","volume":"62","author":"RE Williams","year":"2009","unstructured":"Williams RE, Levine KB, Kalilani L, Lewis J, Clark RV. Menopause-specific questionnaire assessment in US population-based study shows negative impact on health-related quality of life. Maturitas. 2009;62(2):153\u20139.","journal-title":"Maturitas"},{"issue":"5","key":"3073_CR12","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1001\/jama.2022.24140","volume":"329","author":"CJ Crandall","year":"2023","unstructured":"Crandall CJ, Mehta JM, Manson JE. Management of menopausal symptoms: a review. JAMA. 2023;329(5):405\u201320.","journal-title":"JAMA"},{"issue":"1","key":"3073_CR13","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.maturitas.2015.02.003","volume":"81","author":"ECM Neves","year":"2015","unstructured":"Neves ECM, Birkhauser M, Samsioe G, et al. EMAS position statement: the ten point guide to the integral management of menopausal health. Maturitas. 2015;81(1):88\u201392.","journal-title":"Maturitas"},{"issue":"6","key":"3073_CR14","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1097\/GME.0000000000002200","volume":"30","author":"The 2023 Nonhormone Therapy Position Statement of The North American Menopause Society Advisory Panel","year":"2023","unstructured":"The 2023 Nonhormone Therapy Position Statement of The North American Menopause Society Advisory Panel. The 2023 nonhormone therapy position statement of thE North American Menopause Society. Menopause. 2023;30(6):573\u201390.","journal-title":"Menopause"},{"issue":"7","key":"3073_CR15","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1097\/GME.0000000000002028","volume":"29","author":"The Hormone Therapy Position Statement of The North American Menopause Society Advisory Panel","year":"2022","unstructured":"The Hormone Therapy Position Statement of The North American Menopause Society Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767\u201394.","journal-title":"Menopause"},{"issue":"7","key":"3073_CR16","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1080\/13543784.2021.1893305","volume":"30","author":"H Depypere","year":"2021","unstructured":"Depypere H, Lademacher C, Siddiqui E, Fraser GL. Fezolinetant in the treatment of vasomotor symptoms associated with menopause. Expert Opin Investig Drugs. 2021;30(7):681\u201394.","journal-title":"Expert Opin Investig Drugs"},{"key":"3073_CR17","unstructured":"Astellas Pharma US, Inc. VEOZAH\u2122: highlights of prescribing information. 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/216578s003lbl.pdf. Accessed 9 Dec 2024."},{"key":"3073_CR18","unstructured":"European Medicines Agency. Veoza. Annex 1. Summary of Product Characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/veoza-epar-product-information_en.pdf. Accessed 9 Dec 2024."},{"key":"3073_CR19","unstructured":"Astellas Pharma Australia Pty Ltd. VEOZA\u2122 (Fezolinetant): Australian product information. 2024. https:\/\/www.ebs.tga.gov.au\/ebs\/picmi\/picmirepository.nsf\/pdf?OpenAgent=&id=CP-2024-PI-01388-1&d=20240314172310101. Accessed 9 Dec 2024."},{"key":"3073_CR20","unstructured":"Astellas Pharma AG. VEOZATM (Fezolinetant): public risk management plan (RMP) summary. 2024. https:\/\/www.swissmedic.ch\/dam\/swissmedic\/en\/dokumente\/marktueberwachung\/rmp\/fezolinetant_veoza_rmp-summary.pdf.download.pdf\/Fezolinetant_Veoza_Public_Risk_Management_Plan_Summary.pdf. Accessed 9 Dec 2024."},{"key":"3073_CR21","unstructured":"Medicines & Healthcare products Regulatory Agency. Public Assessment Report. National Procedure. Veoza 45 mg film-coated tablets fezolinetant. PLGB00166\/0437 2024. https:\/\/mhraproducts4853.blob.core.windows.net\/docs\/452eebb63cf697a3a4bea8b85ed6effbfa0f7332. Accessed 9 Dec 2024."},{"key":"3073_CR22","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1210\/clinem\/dgad058","volume":"108","author":"KA Johnson","year":"2023","unstructured":"Johnson KA, Martin N, Nappi RE, et al. Efficacy and safety of fezolinetant in moderate-to-severe vasomotor symptoms associated with menopause: a phase 3 RCT. J Clin Endocrinol Metab. 2023;108:1981\u201397.","journal-title":"J Clin Endocrinol Metab"},{"issue":"10382","key":"3073_CR23","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/S0140-6736(23)00085-5","volume":"401","author":"S Lederman","year":"2023","unstructured":"Lederman S, Ottery FD, Cano A, et al. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study. Lancet. 2023;401(10382):1091\u2013102.","journal-title":"Lancet"},{"issue":"4","key":"3073_CR24","first-page":"737","volume":"141","author":"G Neal-Perry","year":"2023","unstructured":"Neal-Perry G, Cano A, Lederman S, et al. Safety of fezolinetant for vasomotor symptoms associated with menopause: a randomized controlled trial. Obstet Gynecol. 2023;141(4):737\u201347.","journal-title":"Obstet Gynecol"},{"issue":"2","key":"3073_CR25","doi-asserted-by":"publisher","first-page":"201","DOI":"10.3390\/ijms17020201","volume":"17","author":"PH Hayashi","year":"2016","unstructured":"Hayashi PH. Drug-induced liver injury network causality assessment: criteria and experience in the United States. Int J Mol Sci. 2016;17(2):201.","journal-title":"Int J Mol Sci"},{"key":"3073_CR26","unstructured":"U.S. Department of Health and Human Services. Guidance for industry drug-induced liver injury: premarketing clinical evaluation. 2009. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/drug-induced-liver-injury-premarketing-clinical-evaluation. Accessed 9 Dec 2023."},{"key":"3073_CR27","unstructured":"U.S. Department of Health and Human Services. Estrogen and estrogen\/progestin drug products to treat vasomotor symptoms and vulvar and vaginal atrophy symptoms\u2014recommendations for clinical evaluation. 2003. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/estrogen-and-estrogenprogestin-drug-products-treat-vasomotor-symptoms-and-vulvar-and-vaginal-atrophy. Accessed 9 Dec 2023."},{"issue":"25","key":"3073_CR28","doi-asserted-by":"publisher","first-page":"7613","DOI":"10.3748\/wjg.v21.i25.7613","volume":"21","author":"CW Brady","year":"2015","unstructured":"Brady CW. Liver disease in menopause. World J Gastroenterol. 2015;21(25):7613\u201320.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"3073_CR29","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1186\/s12889-017-4518-y","volume":"17","author":"PM Trembling","year":"2017","unstructured":"Trembling PM, Apostolidou S, Gentry-Maharaj A, et al. Risk of chronic liver disease in post-menopausal women due to body mass index, alcohol and their interaction: a prospective nested cohort study within the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). BMC Public Health. 2017;17(1):603.","journal-title":"BMC Public Health"},{"issue":"2","key":"3073_CR30","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s00228-021-03213-x","volume":"78","author":"O Laatikainen","year":"2022","unstructured":"Laatikainen O, Sneck S, Turpeinen M. Medication-related adverse events in health care-what have we learned? A narrative overview of the current knowledge. Eur J Clin Pharmacol. 2022;78(2):159\u201370.","journal-title":"Eur J Clin Pharmacol"},{"issue":"10081","key":"3073_CR31","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1016\/S0140-6736(17)30823-1","volume":"389","author":"JK Prague","year":"2017","unstructured":"Prague JK, Roberts RE, Comninos AN, et al. Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flushes: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2017;389(10081):1809\u201320.","journal-title":"Lancet"},{"issue":"3","key":"3073_CR32","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1159\/000495889","volume":"109","author":"M Modi","year":"2019","unstructured":"Modi M, Dhillo WS. Neurokinin 3 receptor antagonism: a novel treatment for menopausal hot flushes. Neuroendocrinology. 2019;109(3):242\u20138.","journal-title":"Neuroendocrinology"},{"issue":"3 Suppl 1","key":"3073_CR33","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1016\/j.amepre.2013.10.029","volume":"46","author":"MC White","year":"2014","unstructured":"White MC, Holman DM, Boehm JE, Peipins LA, Grossman M, Henley SJ. Age and cancer risk: a potentially modifiable relationship. Am J Prev Med. 2014;46(3 Suppl 1):S7-15.","journal-title":"Am J Prev Med"},{"key":"3073_CR34","unstructured":"Cancer Research UK. Cancer incidence for common cancers. 2024. https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/incidence\/common-cancers-compared#heading-Two. Accessed 9 Dec 2024."},{"issue":"6","key":"3073_CR35","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1289\/ehp.1509912","volume":"124","author":"MT Smith","year":"2016","unstructured":"Smith MT, Guyton KZ, Gibbons CF, et al. Key characteristics of carcinogens as a basis for organizing data on mechanisms of carcinogenesis. Environ Health Perspect. 2016;124(6):713\u201321.","journal-title":"Environ Health Perspect"},{"issue":"10413","key":"3073_CR36","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/S0140-6736(23)01634-3","volume":"402","author":"J Douxfils","year":"2023","unstructured":"Douxfils J, Beaudart C, Dogne JM. Risk of neoplasm with the neurokinin 3 receptor antagonist fezolinetant. Lancet. 2023;402(10413):1623\u20135.","journal-title":"Lancet"},{"issue":"10440","key":"3073_CR37","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1016\/S0140-6736(24)00709-8","volume":"403","author":"G Neal-Perry","year":"2024","unstructured":"Neal-Perry G, Santoro N, Cano A, Nappi RE, Shapiro M, Ottery FD. Totality of evidence refutes neoplasm risk with fezolinetant. Lancet. 2024;403(10440):1987\u20138.","journal-title":"Lancet"},{"key":"3073_CR38","unstructured":"van der Vlugt T, Zopf R, Center for Drug Evaluation and Research (CDER). Clinical Review. NDA 216578. TRADENAME (fezolinetant) Tablets. 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2023\/216578Orig1s000MedR.pdf. Accessed 9 Dec 2023."},{"key":"3073_CR39","unstructured":"European Medicines Agency. Annex 1. Summary of product characteristics. Veoza 45 mg film-coated tablets. 2024. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/veoza-epar-product-information_en.pdf. Accessed 9 Dec 2024."},{"issue":"11","key":"3073_CR40","first-page":"6119","volume":"37","author":"K Obata","year":"2017","unstructured":"Obata K, Shimo T, Okui T, et al. Role of neurokinin 3 receptor signaling in oral squamous cell carcinoma. Anticancer Res. 2017;37(11):6119\u201323.","journal-title":"Anticancer Res"},{"issue":"7","key":"3073_CR41","first-page":"881","volume":"29","author":"R Covenas","year":"2014","unstructured":"Covenas R, Munoz M. Cancer progression and substance P. Histol Histopathol. 2014;29(7):881\u201390.","journal-title":"Histol Histopathol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-03073-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-03073-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-03073-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T10:53:10Z","timestamp":1738407190000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-03073-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,30]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["3073"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-03073-8","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,30]]},"assertion":[{"value":"20 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"RK has received consulting\/advisory board fees from Astellas, Pfizer, and Mayne, participated in the data monitoring committee for Astellas (ended), received speaker fees from Pfizer and Astellas, and acted as Medical Advisor for Carrot Fertility. AC acted as former President of the European Menopause and Andropause Society and consulted for Astellas, Theramex, and Viatris. REN received grants from Fidia, consulting fees from Astellas, Besins, Bayer, Exeltis, Fidia, Freya, HRA, Theramex, and Vichy Laboratories, honoraria for lectures from Abbott, Bayer, Exeltis, Novo Nordisk, Organon, Shionogi, Theramex, and Viatris, was a researcher for Fidia, Merck, and Shionogi, and is President Elect of the International Menopause Society. MLE, SM, XW, and FDO are employees of Astellas.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"SKYLIGHT 1, 2, and 4 were conducted in accordance with Declaration of Helsinki, Good Clinical Practice, and International Council for Harmonisation guidelines. An independent ethics committee or institutional review board reviewed ethical, scientific, and medical appropriateness of the study at each site before data collection. Written informed consent was obtained from all participants before any study-related procedures.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}